Grant: CIHR Fellowship
University of Calgary
$45,000.00
Regulation of the brain-specific cholesterol hydroxylase Cyp46A1 as a novel approach for the treatment of prion diseases
EF 2021-22
Résumé
Prion diseases are infectious and fatal neurodegenerative disorders that affect humans and animals. Creutzfeldt-Jakob disease (CJD) is the most common human prion disease. Animal prion diseases include scrapie in sheep/goat and mad cow disease, which has been transmitted to humans from cattle, as well as chronic wasting disease, a contagious prion disease in cervids. Hence, novel approaches are urgently needed to treat those deadly and incurable prion diseases
Cholesterol is a major component of brain cells and is synthesized locally in brain. However, cholesterol excess amount is harmful as it cannot exit the brain. In prion diseases, we know that cholesterol is required for the formation of prions and that the buildup of prions further increases cholesterol levels in the brain. Therefore, regulating brain cholesterol during prion infection could prevent prion disease
The main pathway for brain cholesterol elimination is linked to the brain-specific enzyme, cholesterol 24-hydroxylase (Cyp46A1). Cyp46A1 converts cholesterol into 24(S)-hydroxycholesterol, a molecule that exits the brain. Recently, we reported a reduction of Cyp46A1 levels in the brains of prion-infected mice and CJD patients. We applied the antiretroviral drug, Efavirenz (EFV), an activator of Cyp46A1. EFV treatment significantly delayed the progression of prion disease and increased the survival of the mice.
Notably, the efficiency of most anti-prion drugs depends on the prion strains and is limited in human prion disease. Therefore, our goal is to test the therapeutic effects of Cyp46A1 overexpression and EFV treatment in human CJD prion-infected primary neuronal culture and CJD prion-inoculated humanized transgenic mice. Hence, upon successful outcomes of this study, the Cyp46A1 would be a promising therapeutic target, and its regulation either using EFV medication or overexpression is a valuable approach for the treatment of human prion diseases which will benefit Canadians and global health
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
454456
Name
Ali Tahir
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Regulation of the brain-specific cholesterol hydroxylase Cyp46A1 as a novel approach for the treatment of prion diseases
Programtype2
Fellowship Programs
Orgnameinp2
University of Calgary
Cihramount2
$45,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Brain Cholesterol Metabolism; Cellular Models Of Prion Diseases; Cholesterol 24-Hydroxylase (Cyp46a1); Cyp46a1 Activator (Efavirenz); Fda-Approved Repurposed Drug (Efavirenz); Human Prion Diseases; Mouse Models Of Human Prion Diseases; Neurodegenerative Diseases; Neurosciences; Treatment Of Human Prion Disease
Abstract
Prion diseases are infectious and fatal neurodegenerative disorders that affect humans and animals. Creutzfeldt-Jakob disease (CJD) is the most common human prion disease. Animal prion diseases include scrapie in sheep/goat and mad cow disease, which has been transmitted to humans from cattle, as well as chronic wasting disease, a contagious prion disease in cervids. Hence, novel approaches are urgently needed to treat those deadly and incurable prion diseases
Cholesterol is a major component of brain cells and is synthesized locally in brain. However, cholesterol excess amount is harmful as it cannot exit the brain. In prion diseases, we know that cholesterol is required for the formation of prions and that the buildup of prions further increases cholesterol levels in the brain. Therefore, regulating brain cholesterol during prion infection could prevent prion disease
The main pathway for brain cholesterol elimination is linked to the brain-specific enzyme, cholesterol 24-hydroxylase (Cyp46A1). Cyp46A1 converts cholesterol into 24(S)-hydroxycholesterol, a molecule that exits the brain. Recently, we reported a reduction of Cyp46A1 levels in the brains of prion-infected mice and CJD patients. We applied the antiretroviral drug, Efavirenz (EFV), an activator of Cyp46A1. EFV treatment significantly delayed the progression of prion disease and increased the survival of the mice.
Notably, the efficiency of most anti-prion drugs depends on the prion strains and is limited in human prion disease. Therefore, our goal is to test the therapeutic effects of Cyp46A1 overexpression and EFV treatment in human CJD prion-infected primary neuronal culture and CJD prion-inoculated humanized transgenic mice. Hence, upon successful outcomes of this study, the Cyp46A1 would be a promising therapeutic target, and its regulation either using EFV medication or overexpression is a valuable approach for the treatment of human prion diseases which will benefit Canadians and global health
Competitiondate
202110
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ali, Tahir
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $45,000~ $0~